Cangrelor
Top View
- Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in Vivo by Decreasing of Fibrinogen Density in Thrombus
- Original Article Efficacy and Safety of Cangrelor for Patients with Coronary Artery Disease: a Meta-Analysis of Four Randomized Trials
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Microglia and Neuroinflammation: What Place for P2RY12?
- Heterogeneity in Platelet Exocytosis
- 2018.01 Platelet-Aggregation Inhibitors.Pdf
- Cangrelor to Reduce Platelet Aggregation and Thrombosis in Patients Undergoing Percutaneous Coronary Intervention99
- Antiplatelet Therapy Plays a Very Important Role in Preventing the Past, Present and Future
- (12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
- Kengrexal, INN-Cangrelor Tetrasodium
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Platelet Purinergic Receptors in Thrombosis and Inflammation Gachet, Hechler
- Cangrelor for the Management and Prevention of Arterial Thrombosis
- Cangrelor Induces More Potent Platelet Inhibition Without Increasing Bleeding in Resuscitated Patients
- Intravenous Platelet Blockade with Cangrelor During PCI
- Customs Tariff - Schedule Xxi - 1
- Oregon Drug Use Review / Pharmacy & Therapeutics Committee
- Cangrelor Ameliorates CLP-Induced Pulmonary Injury in Sepsis by Inhibiting GPR17